Operating cash flow increased 51.8%
Operating cash flow changed +51.8% from the comparable as-filed period.
-$2.4M→-$1.1M3 prior comparisons
GROSSPATTERN / DETERMINISTIC EVIDENCE / V3
Search securities →ALZN financial changes
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Shares outstanding increased 53.7%
Shares outstanding changed +53.7% from the comparable as-filed period. The change ranks at the 62th percentile of 8 prior comparable changes.
3,139,861→4,825,7238 prior comparisons
Research & development decreased 37.6%
Research & development changed -37.6% from the comparable as-filed period.
$1.7M→$1.1M3 prior comparisons
Cash & equivalents increased 35.1%
Cash & equivalents changed +35.1% from the comparable as-filed period.
$5.6M→$7.6M3 prior comparisons
Stock-based compensation increased 79.9%
Stock-based compensation changed +79.9% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
$42,902→$77,1994 prior comparisons
Operating income decreased 12.0%
Operating income changed -12.0% from the comparable as-filed period.
-$2.7M→-$3.0M3 prior comparisons
Current assets increased 39.2%
Current assets changed +39.2% from the comparable as-filed period.
$5.9M→$8.3M3 prior comparisons
Total assets increased 35.0%
Total assets changed +35.0% from the comparable as-filed period.
$6.3M→$8.5M3 prior comparisons
Net income decreased 12.0%
Net income changed -12.0% from the comparable as-filed period.
-$2.7M→-$3.0M3 prior comparisons
Stockholders' equity increased 8.6%
Stockholders' equity changed +8.6% from the comparable as-filed period.
$5.3M→$5.8M1 prior comparisons
Operating income decreased 111.8%
Operating income changed -111.8% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
-$1.0M→-$2.2M2 prior comparisons
Net income decreased 111.6%
Net income changed -111.6% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
-$1.0M→-$2.2M2 prior comparisons
Research & development increased 186.0%
Research & development changed +186.0% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
$447,111→$1.3M2 prior comparisons
Cash & equivalents decreased 19.2%
Cash & equivalents changed -19.2% from the comparable as-filed period.
$3.4M→$2.7M0 prior comparisons
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.